The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | Artificial intelligence in myeloma
Jill Corre, PharmD, PhD, of L’Institut Universitaire du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire, Toulouse, France, discusses machine learning, a branch of artificial intelligence, and its prospects in the field of myeloma treatment and diagnosis. Dr Corre explains that adopting machine learning may be a crucial step in the advancement for myeloma, such as for the identification of high-risk patients with complex disease. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
